A possible association between high-risk human papillomaviruses (HPV) and lung cancer has been investigated for decades with discrepant results. The aim of this study was to determine the prevalence of HPV16 and 18 in Bulgarian patients with lung cancer. Two hundred and nine biopsy specimens from patients with histologically proven lung cancer and without cancer were analyzed. Each sample was subjected to three parallel PCRs using broad spectrum GP5þ/6þ primers and type-specific (TS) primers for HPV types 16 and 18. Of the 132 lung carcinoma samples, 33 (25%) were positive for HPV16 and/or HPV18 by TS PCR whereas only five (3.8%) samples were HPV positive by consensus PCR. All non-malignant controls were HPV negative. HPV18 was the more prevalent, being found in 11.4% of samples, followed by HPV16 in 9.1% samples; 4.5% of lesions were positive for both HPV16 and HPV18. HPV16/18 were most prevalent in small cell carcinoma (29.2%) and least prevalent in squamous cell carcinoma (23.3%). HPV was only detected in squamous cell carcinoma and adenosquamous carcinoma by consensus PCR. This study revealed a high HPV16/18 prevalence in lung carcinoma samples from Bulgarian patients when TS PCR was used to detect them. The difference between HPV positivity as detected by consensus and by TS PCR was significant, indicating the importance of methodological issues in explaining the discrepancies between previous studies. HPV18 was more common than HPV16. No association between HPV16/18 status and histopathological diagnosis was identified.
Lung cancer is the leading cause of cancer morbidity and mortality worldwide. However, the molecular mechanisms of lung carcinogenesis have not been completely clarified. Epidemiological and experimental data suggest that tobacco smoking is the most important risk factor for the development of lung cancer, other risk factors are environmental pollution and genetic factors. However, not every case of lung cancer is associated with known risk factors. In addition, most smokers do not develop lung cancer. All these observations indicate that other factors may play roles in development of this malignancy.
It has been proven that certain types of human papillomavirus (HPV) are the main cause of cervical cancer. HPV is also involved in development of other anogenital and also oropharyngeal cancers (1) . In 1979, Syrj€ anen first suggested that high-risk HPV may play a role in lung carcinogenesis (2) . Since then, a number of studies have suggested an association between HPV infection and development of lung cancer. A recent international pooled analysis has shown that lung cancer tissues are almost fourfold more likely to be HPVpositive than normal lung tissues (3) . A meta-analysis of 7381 lung cancers from different geographical regions reported an average of 22.4% HPV positivity with significant heterogeneity between the studies. Further, HPV positivity in lung cancer is much higher in Asia and South America than in Europe and North America, indicating regional differences in associations between lung cancer and HPV prevalence (4) . However, the role of HPV in the development of lung cancer is still unclear. In part because wide variations in HPV infection rates reported for these cancers may be attributable to the geographical origin of the study, histological types of cancer, HPV detection method, type of tested samples (frozen or paraffin-embedded samples) and so on (3) (4) (5) .
According to a number of studies, HPV16 and HPV18 are the most commonly detected HPV genotypes in lung cancer (3, 5) . This is an important observation because HPV16 and HPV18 are HPV vaccine types and prophylactic HPV vaccines are currently in use worldwide, including in Bulgaria.
In Bulgaria, lung cancer is the commonest malignancy and the commonest cause of cancer death in men, representing 19 .3% of all new cancer cases and 27.5% of cancer deaths in men (6). Moreover, its incidence and mortality are increasing each year. According to the National Cancer Registry, lung cancer incidence and mortality among men in Bulgaria are higher than the European average. However, there are no data about a link between HPV and lung cancer in Bulgaria. The aim of this study was to screen Bulgarian patients with lung cancer for the prevalence of high risk HPV types 16 and 18 to enable prediction of the potential impact of prophylactic HPV vaccines on reduction of lung cancer in Bulgaria.
MATERIALS AND METHODS

Lung samples
Two hundred and nine biopsy specimens (FFPE and fresh frozen) from patients with histologically proven lung cancer (n ¼ 141) and without cancer (n ¼ 68) were analyzed. The specimens were obtained from the National Oncology Hospital and the Fifth MBAL, Sofia. The lung cancers included 78 SCCs, 15 ACs, 17 ASCs, 25 SmCCs and six others (four poorly differentiated and two neuroendocrine tumors). The samples were obtained from109 men and 32 women with a mean age of 69 years (range 35-82 years). All lung cancers were clinically considered to be primary lung cancers. The 68 non-cancer samples obtained from patients with various lung diseases (hamartoma, chronic obstructive pulmonary disease, bronchiectasis, inflammatory pseudotumors, lung abscess, sarcoidosis) were used as negative controls. These samples were from 43 men and 25 women, with an average age of 59 years (range 30-82 years). The study was approved by the Ethics Committee of National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
HPV testing by PCR
Thin sections were cut from FFPE tissues using a new scalpel for each paraffin block. Total DNA was extracted using a QIAamp DNA FFPE Tissue Kit (Qiagen, Duesseldorf, Germany). DNA was extracted from frozen samples with a GeneJET Genomic DNA Purification Kit (Thermo Scientific, Vilnius, Lithuania) or PureLink Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA). All extractions were performed according to the manufacturer's instructions and care was taken to prevent specimen cross contamination. The quality of extracted DNA of each specimen was evaluated by bglobin gene amplification.
For b-globin gene detection a GH20/PC04 primer set was used to amplify a 268 bp fragment, as previously described (7). Detection of HPV was based on two PCR systems: consensus PCR and TS PCR. Each b-globinpositive sample was subjected to three parallel PCRs using broad spectrum GP5þ/6þ primers and TS primers for HPV types 16 and 18. A 150 bp fragment of HPV L1 gene was amplified by consensus PCR using GP5þ/ GP6þ primers, as previously reported (8) . This PCR system detects up to 44 different HPV genotypes. TS PCR targeted the E6/E7 region of the HPV16 genome (amplicon size ¼ 96 bp) and the L1 region of the genome for HPV18 (amplicon size ¼ 115 bp). TS PCR was performed as previously reported using TS primer pairs developed by Baay et al. to detect HPV 16 and 18 in FFPE samples (9, 10) . All amplifications were in a total volume of 50 mL including 5 mL template DNA with AmpliTaq Gold 360 Master Mix (Applied Biosystems, Foster, CA, USA). Primers used in this study were synthesized by Bioneer (Daejeon, South Korea). Amplifications were performed on a DNA Engine Opticon 2 system (MJ Research, Waltham, MA, USA).
Positive and negative controls were included in each run. Cell lines SiHa (HPV 16) and HeLa (HPV 18) were used as positive controls and distilled water as negative control.
Ten microliters of the amplification products were analyzed by electrophoresis in 2% agarose gels, stained with ethidium bromide and observed under UV illumination.
Data analysis
Statistical analysis was performed with SPSS for Windows v.10.0 using Fisher exact test to calculate P values. P values of less than 0.05 were considered to denote statistical significance.
RESULTS
Of 209 lung biopsy specimens subjected to DNA quality assessment, 194 were b-globin positive and were further tested for presence of HPV DNA using two PCR systems; namely consensus PCR and TS PCR. All 15 b-globin negative DNA samples were extracted from FFPE blocks. Of the 132 b-globin positive lung carcinoma samples 33 (25%) were identified as being positive for HPV16 and/ or HPV18 DNA by TS PCR and only five (3.8%) as HPV positive by consensus GP5þ/6þ PCR system. All 62 bglobin positive non-malignant controls were HPV negative by both consensus and TS PCR systems (Table 1) .
HPV 18 was more prevalent, being found in 15/132 (11.4%) b-globin positive samples, followed by HPV16 detected in 12/132 (9.1%) samples; 4.5% of samples were positive for both HPV16 and HPV18 ( Table 2) .
The 
DISCUSSION
In our study, we detected HPV DNA in a small proportion (3.8%) of lung cancer biopsies when they were tested by consensus GP5þ/6þ PCR. Similar HPV prevalence has been determined by PCR-based methods in other European countries: France (2%), Croatia (3.6%), Greece (3.7%), Norway (3.9%), Italy (4%), Turkey (5%) and Finland (5.2%) (4, (11) (12) (13) (14) (15) (16) . However, a number of European studies have failed to detect any HPV DNA in lung carcinomas (17) (18) (19) .
It has been established by previous studies that the predominant HPV types found in lung cancer are HPV 16 and HPV18. When we tested the same samples using HPV16 and HPV18 type specific primers the HPV16/18 detection rate reached 25%. The higher HPV16/18 prevalence found in this study was most likely attributable to the higher sensitivity of TS PCR compared with consensus PCR system. Similarly, according to some reviews of published reports, the observed variations in HPV prevalence in lung cancer between studies may be attributable to methodological issues (5, 20) . Further, in our study most of our samples were FFPE lung cancer tissues. It is known that DNA degradation occurs in paraffin-embedded tissue and that amplification of large target sequences is challenging. We therefore used primers that amplified relatively short fragments of the HPV16 and HPV18 genomes, 96 bp and 115 bp, respectively, which may have contributed to increasing amplification efficiency and accordingly HPV16/18 positivity. This primer system was successfully used in our previous study of HPV prevalence in invasive cervical carcinomas in Bulgaria (9) . The high HPV16/18 prevalence in lung cancer tissues observed in our current study indicates that HPV may be a factor in lung tumorigenesis. Additionally, the finding that HPV was found in tumor tissues but not in cancerfree samples supports the hypothesis of an oncogenic role for HPV16/18. However, further studies are needed. Additionally, it should be taken into account that there were fewer non-cancer controls than lung cancer samples and that the normal lung tissues were from patients without cancer, not from normal tissue adjacent to lung cancer.
The HPV16/18 prevalence we detected in Bulgarian patients with lung cancer is substantially higher than that reported by most performed in other European countries (3, 20) . It is quite possible that other factors, such as smoking habits, sexual behavior and HPV prevalence in Bulgaria contributed to the higher HPV16/ 18 positivity detected in our study. Although Bulgaria has a high proportion of smokers, data regarding smoking status of participants in this study were not available. Although there are some data indicating high HPV prevalence in Bulgaria, there is little information on HPV epidemiology, including incidence of HPV in the general population in Bulgaria. Of interest, a number of authors have reported findings similar to ours or even higher HPV positivity rates in lung cancer tissues: 21% in Italy, 30% in Finland, 49% in Norway, 69% and 19% in Greece (21) (22) (23) (24) (25) . In addition, some recent publications have indicated a positive link between HPV and etiopathogenesis of lung carcinoma, supporting the present findings (26, 27) . However, others have failed to identify such a causative link (28) .
Further, we found that HPV 18 is more prevalent (11.4%) than HPV16 (9.1%) in lung cancer samples. These observations are opposite to those of most previous studies. According to a recent international pooled analysis, in each geographic region studied the prevalence of HPV16 was significantly higher than that of HPV18, with the exceptions of North America and Asia (3). However, HPV 18 was the most frequent type detected in Greece and Turkey (13, 16, 29) . The higher HPV18 prevalence detected in the current study is most likely specific to lung cancer because, in contrast, we have found higher prevalence of HPV16 than of HPV18 in cervical cancers (9). According to a meta-analysis, the histological type of cancer could explain variability in HPV detection rates in lung cancer tissue (4) . Therefore, we evaluated HPV status according to the histopathological diagnosis. When tested by consensus GP5þ/6þ PCR, the presence of HPV was restricted to SCC (5.5%) and ASC (6.2%), the rates being similar. For neighboring Greece, using the same PCR system, HPV was more often detected in ASC (20%) than in SCC (10%) samples. In addition, those authors found HPV positivity in 24% of AC samples (25) . Significant variability in HPV prevalence in different histological types of lung cancer has been reported around the globe. According to a meta-analysis, HPV prevalence in SCCs ranges from 0.0 to 48.1% and in ACs from 0.0 to 44.4%, whereas it ranges from 0.0 to 100.0% for ASCs and SmCCs (20) .
When we used HPV 16 and HPV 18 TS PCR, we detected HPV16/18 in all tested histological types at similar prevalence rates ranging from 23.3% (SCC) to 29.1% (SmCC), indicating no association between HPV16/18 status and histology. Similar observations have been reported by others. For example, a study of 304 patients with SCC and AC from Asia found no significant difference in HPV prevalence between these histological types (SCC vs. AC, 6.3% vs. 7%) (30) . Further, an Iranian study detected HPV in 25% of SCCs, 21% of ACs and 29% of SmCCs and identified no association with any histological type (31) . However, an association between HPV 16/18-positivity in lung tumors and histology has been reported by others. It is suspected that HPV predisposes individuals to particular histological subtypes of lung cancer. Aguayo et al. observed statistically significant differences in HPV 16 prevalence between histological cancer types: they detected HPV16 in 44% SCCs, whereas ACs and SmCCs were HPV16 negative (32) . A Chinese study found that HPV infection is more prevalent in SCC (59.8%) than in AC (17.5%) (33) . In our study, we detected both HPV16 and HPV 18 in all tested histological types; however, HPV18 was more common than HPV16 in AC (20.0% vs. 6.6%) and SmCC (12.5% vs 8.3%) cases. This finding is opposite to those of previous studies, which have reported higher prevalence of HPV16 than of HPV18 in all histological types (20) .
We found similar rates of HPV16/18 prevalence in all histological types, indicating there is most likely no association between HPV and lung cancer histology. However, the differences in number of samples of each histological type should be considered. More than 50% (73/132) of our lung cancer samples were SCCs, whereas there were far fewer ACs (14/132), ASCs (16/132), SmCCs (23/132) and other tumors (4/132).
In summary, our study showed a high HPV16/18 prevalence in lung carcinoma samples from Bulgarian patients when we used TS PCR as the detection method, indicating a potential role of HPV as a risk factor for lung cancer in this country. There was a significant difference in HPV positivity detected by consensus and TS PCR, confirming the importance of methodological issues in explaining reported discrepancies. HPV18 was more common than HPV16, contrary to cervical cancer. We did not identify any association between HPV16/18 status and histopathological diagnosis.
